A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Recruiting · NCT07562581 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 2 | 2026-09-02 | NCT07562581 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 24 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shanghai Chest Hospital | Shanghai | China | 11 |